FASEB SRC on Hematopoietic Malignancies

FASEB SRC 造血系统恶性肿瘤

• 批准号: 8199824
• 负责人: John D Crispino
• 金额: $ 0.5万
• 依托单位: FEDERATION OF AMER SOC FOR EXPER BIOLOGY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8199824
• 关键词: Academy; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Acute Promyelocytic Leukemia; Adult; American Society of Hematology; Animal Model; Area; Arsenic Trioxide; Basic Science; Biological Markers; Biology; Cells; Childhood; Chromatin Structure; Chromosomal translocation; Chronic Myeloid Leukemia; Clinical; Clinical Trials; Collaborations; Commit; DNA Methylation; Development; Disease; Environment; Fostering; Genomics; Gleevec; Goals; Hematologic Neoplasms; Hematological Disease; Hematopoiesis; Hematopoietic; Hematopoietic Neoplasms; Histone Acetylation; Human Genome Project; Investigation; JAK2 gene; Journals; Learning; Malignant Neoplasms; Metabolic; Methylation; MicroRNAs; Molecular; Morbidity - disease rate; Multiple Myeloma; Mutation; Myeloproliferative disease; Participant; Pathogenesis; Pathologic; Patients; Pharmaceutical Preparations; Physicians; Postdoctoral Fellow; Publications; Research; Research Personnel; Resistance; Role; Rural; Schools; Scientist; Signal Transduction; Site; Staging; Stem cells; Students; Syndrome; Systems Biology; Therapeutic; Training; Transcriptional Regulation; Travel; Tretinoin; United States National Institutes of Health; Vermont; Yang; base; cancer cell; cancer diagnosis; cancer therapy; distraction; functional genomics; graduate student; improved; inhibitor/antagonist; interest; leukemia; leukemia/lymphoma; meetings; mortality; notch protein; novel; novel therapeutics; oncology; physical science; protein protein interaction; stem; stem cell biology; stem cell therapy; success; symposium

DESCRIPTION (provided by applicant): The FASEB Summer Research Conference on Hematopoietic Malignancies is a highly focused and interactive meeting of physicians and scientists who are dedicated to the study of blood diseases and are committed to developing improved therapies for patients. Unlike the annual American Society of Hematology Meeting, which draws well over 15,000 participants, the FASEB meeting, is restricted to 175 attendees and thus provides a collaborative and supportive environment for trainees to meet with leaders in the field. The 2011 meeting will highlight recent advances in biology and treatment of a wide spectrum of blood cancers, including acute myeloid leukemia, acute lymphoid leukemia, myeloma, myeloproliferative neoplasms and myeloproliferative diseases. In addition, this year's meeting will include sessions on systems biology of hematopoiesis, stem cell biology, and the role of metabolic mutations in hematologic malignancies. We will hold special "Meet the Expert" and "Meet the Editor" sessions, where trainees can interact one on one with leaders in the field and with Dr. Helena Yang, editor of the journal Cancer Cell. The site of the 2011 meeting will once again be the Vermont Academy, a small boarding school in rural Vermont. This site is an ideal setting, because the participants have few distractions and are available to interact with students and post-docs throughout the day. The meeting will emphasize the following key areas: 1) The identification of oncometabolites and their implications for blood cancer treatment and diagnosis; 2) Normal hematopoietic stem and progenitor cell development for understanding leukemia stem cell (LSC) biology; 3) Mechanisms of altered transcriptional regulation in hematopoietic neoplasms, with a particular focus on changes in DNA methylation as well as histone acetylation, methylation and chromatin structure; 4) Role of microRNAs in CLL pathogenesis and as cancer biomarkers; 5) Lessons learned from the use of animal models; identification of LSCs and anti- LSC therapies; 6) The impact of the human genome project in investigations of hematological malignancies, with an emphasis on functional genomics; 7) Application of systems biology approaches to hematopoietic malignancies and LSC biology; and 8) Recent therapeutic advances based on a molecular understanding of the diseases; e.g. Notch inhibitors in T-ALL; mechanisms of Gleevec resistance and sensitivity in chronic myeloid leukemia, use of arsenic trioxide in APL and CLL, and efforts to utilize JAK inhibitors in myeloproliferative neoplasms. Support from the NIH will be used to provide registration and lodging for trainees and early stage investigators and a small subset of invited speakers. PUBLIC HEALTH RELEVANCE: Although there have been major breakthroughs in treating a few subtypes of hematologic malignancies, such as the use of Gleevec in chronic myeloid leukemia, the majority of blood cancers remain major causes of morbidity and mortality of both adult and pediatric patients. The FASEB Summer Research Conference on Hematopoietic Malignancies serves to bring together basic, translational, and clinical researchers for an insightful and productive exchange of latest discoveries. The meeting also fosters new collaborations and the training of graduate students, post---doctoral fellows and early stage investigators in this important research field.

描述（由申请人提供）：FaseB夏季造血恶性肿瘤的研究会议是一次高度集中和互动的医师和科学家会议，他们致力于研究血液疾病，并致力于为患者开发改进的治疗疗法。与吸引超过15,000名参与者的年度美国血液学会议不同，FaseB会议仅限于175名与会者，因此为受训者提供了一个协作和支持的环境，以与该领域的领导人会面。 2011年的会议将重点介绍各种血液癌的生物学和治疗的最新进展，包括急性骨髓性白血病，急性淋巴白血病，骨髓瘤，骨髓增生性肿瘤和脊髓增生性疾病。此外，今年的会议将包括有关造血，干细胞生物学系统生物学的会议，以及代谢突变在血液学恶性肿瘤中的作用。我们将举行特别的“与专家”和“见面编辑”会议，学员可以与该领域的领导者以及期刊癌细胞编辑Helena Yang博士一对一互动。 2011年会议的地点将再次成为佛蒙特州农村的一所小型寄宿学校的佛蒙特学院。该网站是理想的环境，因为参与者的干扰很少，并且可以全天与学生和毕业后互动。会议将强调以下关键领域：1）鉴定oncometabolites及其对血液癌治疗和诊断的影响； 2）正常的造血干和祖细胞发育，以了解白血病干细胞（LSC）生物学； 3）造血肿瘤中转录调节改变的机制，特别关注DNA甲基化以及组蛋白乙酰化，甲基化和染色质结构的变化； 4）microRNA在CLL发病机理和癌症生物标志物中的作用； 5）从使用动物模型中学到的教训； LSC和抗LSC疗法的鉴定； 6）人类基因组项目对血液学恶性肿瘤的研究的影响，重点是功能基因组学； 7）系统生物学方法应用于造血恶性肿瘤和LSC生物学； 8）基于对疾病的分子理解的最新治疗进展；例如T-ALL中的缺口抑制剂；慢性髓样白血病中Gleevec耐药性和敏感性的机制，在APL和CLL中使用砷三氧化物的机制，以及在骨髓增生性肿瘤中利用JAK抑制剂的努力。 NIH的支持将用于为学员和早期调查员提供注册和住宿，以及一小部分被邀请的演讲者。 公共卫生相关性：尽管治疗几种血液系统恶性肿瘤的亚型（例如在慢性髓样白血病中使用Gleevec）取得了重大突破，但大多数血液癌仍然是成人和儿科患者的发病率和死亡率的主要原因。 FASEB夏季造血恶性肿瘤研究会议有助于将基本，转化和临床研究人员汇集在一起​​，以实现最新发现的深刻和富有成效的交流。会议还促进了新的合作和研究生的培训，邮政博士学位和早期研究人员在这个重要的研究领域。